


SUPPLEMENTARY



Supplementary Figure S1: Symptoms during the follow-up evaluation. The graph shows the frequency of the most common symptoms during the follow-up visits expressed as percentage.

Supplementary Table S1: Univariate analysis of clinical variables and Gas6/sTAM among patients with and without residual symptoms. Evaluation of possible association between residuals symptoms at one year follow-up visits and clinical variables: CIRS, DLCO, age, Gas6, sAxl, sMer, gender and class of severity. Continuous variables are presented as medians and interquartile range [IQR], while categorical variables as an absolute number (%). Bold text highlights the statistically significant results. For abbreviation: CIRS, cumulative illness rating scale; DLCO, diffusing capacity of carbon monoxide in lungs.

VARIABLES	NO RESIDUAL SYMPTOMS (n=165)	RESIDUAL SYMPTOMS (n=98)	p-value
	Median [IQR]	Median [IQR]	
CIRS	2.0 [1-4]	2.0 [2-4]	0.43
DLCO, %	83.0 [72-96]	76.0 [66-84]	0.0002
Age, years	60 [51-67]	61 [50-70]	0.47
Gas6 (ng/ml)	28.36 [23.4-35.63]	28.90 [24-36,47]	0.37
sAxl (ng/ml)	66.44 [55.59-76.65]	60.60 [50.9-74.1]	0.036
sMer (ng/ml)	8.53 [7.07-10.38]	8.96 [7.4-10.25]	0.49

Sex (male/female)		116 (70.3%)/49 (29.7%)	46 (46.9%)/52 (53.1%)	0.0002
Class of severity	3	24 (14.5%)	16 (16.3%)	0.64
	4	3 (1.8%)	2 (2%)	
	5	59 (35.8%)	27 (27.6%)	
	6	71 (43%)	44 (44.9%)	
	7	8 (4.9%)	9 (9.2%)	
Symptoms at the follow-up evaluation		165 (62.7%)	98 (37.2%)	0.0001

Supplementary Table S2: Results of the questionnaire assessing the features of hair loss.

When did you start notice hair loss?		
1. Early after hospital discharge		21/59 (35.6%)
2. Months after hospital discharge		38/59 (64.4%)
Type of hair loss		
1. Acute/massive		44/59 (74.6%)
2. Chronic		15/59 (25.4%)
Characteristics of hair loss		
1. Increased number of falling hair		36/59 (78.0%)
2. Thinning hair without increased of falling hair		13/59 (22.0%)
How did you observed hair loss?		
1. While washing your hair		23/59 (39.0%)
2. While drying your hair		1/59 (1.7%)
3. While combing your hair		23/59 (39.0%)
4. Presence of hair on the bathroom floor		1/59 (1.7%)
5. Presence of hair on the pillow in the morning		11/59 (18.6%)
How long did you notice hair loss?		
1. Less than 1 year		42/59 (71.2%)
2. More than 1 year		17/59 (28.8%)
Concomitant pathologies		
1. No one		50/59 (84.7%)
2. Thyroiditis		7/59 (11.9%)
3. Vitiligo		0/59 (0%)
4. Polycystic ovary		2/59 (3.4%)
Previous diagnosis or treatments for alopecia		
1. Yes		2/59 (3.4%)
2. No		57/59 (96.6%)
Family history for alopecia		
1. Yes		5/59 (8.5%)
2. No		54/59 (91.5%)
Concomitant or previous therapies		
1. No one		44/59 (74.5%)
2. Chemotherapy or immunotherapy		1/59 (1.7%)

3. Anticoagulants	3/59 (5.1%)
4. Antiepileptic	0/59 (0%)
5. Beta-blockers	7/59 (11.9%)
6. Tricyclic antidepressant	1/59 (1.7%)
7. Anticoagulants and beta-blocker together	3/59 (5.1%)
Nutritional deficiencies	
1. No one	26/59 (44.0%)
2. Supplementation of iron	2/59 (3.4%)
3. Supplementation of calcium	1/59 (1.7%)
4. Supplementation of Vitamin D	27/59 (45.8%)
5. Supplementation of calcium and vitamin D	3/59 (5.1%)
Area of interest	
1. Forehead	14/59 (23.7%)
2. On top of the head	12/59 (20.3%)
3. Spread all over the head	27/59 (45.8%)
4. Patches on the head	6/59 (10.2%)
Characteristics of falling hair	
1. Normal	37/59 (62.7%)
2. Thinned	20/59 (33.9%)
3. Broken	2/59 (3.4%)
Slowdown in hair growth rate	
1. Yes	22/59 (37.3%)
2. No	37/59 (62.7%)
Other area of interest	
1. No one	54/59 (91.5%)
2. Eyelashes	3/59 (5.1%)
3. Eyebrows	1/59 (1.7%)
4. Beard	1/59 (1.7%)
Presence of lesions on the scalp	
1. No one	51/59 (86.4%)
2. Pustules	4/59 (6.8%)
3. Scales	3/59 (5.1%)
4. Atrophic areas	1/59 (1.7%)
Visual perception of thinning	
1. Only by participant him/herself	21/59 (35.6%)
2. By Participant and other people	38/59 (64.4%)
Impact on quality of life	
1. Yes	18/59 (30.5%)
2. No	41/59 (69.5%)
Necessity to hide the hair loss	
1. Yes	8/59 (13.6%)
2. No	51/59 (86.4%)
Associated symptoms	
1. No one	40/59 (67.8%)
2. Itching	12/59 (20.3%)
3. Pain	1/59 (1.7%)
4. Burning	5/59 (8.5%)
5. Hyperesthesia	1/59 (1.7%)
Treatment	
1. No one	47/59 (79.6%)
2. Topic	5/59 (8.5%)
3. Systemic	7/59 (11.9%)

Duration of treatment	
1. 1 month	2/12 (16.7%)
2. 2 months	2/12 (16.7%)
3. 3 months	2/12 (16.7%)
4. 4 months	2/12 (16.7%)
5. 6 months	4/12 (33.2%)
Outcome	
1. Resolved	45/59 (76.3%)
2. Not resolved	14/59 (23.7%)